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Abstract
Purpose: A lower daily pill burden may improve adherence to antiretroviral treatment (ART) and clinical outcomes in
patients with human immunodeficiency virus (HIV). This study assessed differences in adherence using the number of pills
taken per day, and evaluated how adherence correlated with hospitalization.
Methodology: Commercially insured patients in the LifeLink database with an HIV diagnosis (International Classification of
Diseases, 9th Revision, Clinical Modification code 042.xx) between 6/1/2006 and 12/31/2008 and receipt of a complete ART
regimen were selected for inclusion. Patients were grouped according to their daily pill count and remained on ART for at
least 60 days. Outcomes included adherence and rates of hospitalization. Adherence was measured as the proportion of
days between the start and end of the regimen in which the patient maintained supply of all initiated ART components.
Logistic regressions assessed the relationship between pills per day, adherence, and hospitalization, controlling for
demographics, comorbidities, and ART-naı ¨ve (vs. experienced) status.
Results: 7,073 patients met the study inclusion criteria, and 33.4%, 5.8%, and 60.8% received an ART regimen comprising
one, two, or three or more pills per day, respectively. Regression analysis showed patients receiving a single pill per day
were significantly more likely to reach a 95% adherence threshold versus patients receiving three or more pills per day (odds
ratio [OR]=1.59; P,0.001). Regardless of the number of pills received per day, patients were over 40% less likely to have a
hospitalization if they were adherent to therapy (OR=0.57; P,0.001). Patients receiving a single pill per day were 24% less
likely to have a hospitalization versus patients receiving three or more pills per day (OR=0.76; P=0.003).
Conclusions: ART consisting of a single pill per day was associated with significantly better adherence and lower risk of
hospitalization in patients with HIV compared to patients receiving three or more pills per day.
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Introduction
Adherence to antiretroviral therapy (ART) is important for
achieving optimal clinical outcomes in individuals with human
immunodeficiency virus (HIV) or acquired immune deficiency
syndrome (AIDS). Patients with poor adherence to ART are at an
increased risk for incomplete viral suppression, disease progres-
sion, and death [1–5]. Combination ART initially was character-
ized by high pill burdens and multiple daily doses. More recently,
fixed-dose combinations and agents with prolonged half-lives have
allowed for markedly simpler regimens: notably, all the preferred
initial treatments for HIV or AIDS under current treatment
guidelines consist of four or fewer pills per day with once- or twice-
daily dosing [6,7].
Clinical trials and cohort studies suggest that an ART regimen
composed of a single pill per day may significantly improve
adherence, patient satisfaction, and virological outcomes [8–11].
In prospective studies of patients switching to single-pill treat-
ments, adherence to an ART regimen has been estimated to be up
to 98% in prospective trials [8–10]. While adherence was high in
these patients prior to the switch, it numerically improved in some
of the studies after switching to fewer daily pills. Furthermore,
among homeless or marginally housed patients, those receiving
an ART regimen composed of a single pill per day had better
virologic outcomes and a 26% increase in adherence, compared
with patients receiving other multi-pill per day regimens [11].
Although these studies support the adherence benefit of an ART
regimen composed of a single pill per day, limited data exist on
individuals with HIV or AIDS receiving this regimen in clinical
practice. Therefore, the primary objective of this retrospective
database analysis was to assess the effect of ART as a single pill per
day on adherence and hospitalization in a large population of
managed care enrollees in the United States who received
treatment for HIV or AIDS.
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Data for this analysis were taken from the LifeLink database
(formerly the PharMetrics Integrated Outcomes database), a
national insurance claims database encompassing 95 United States
managed care organizations covering over 61 million lives between
1997 and 2008. This database contains patient-level demographics,
periods of health plan enrollment, primary and secondary dia-
gnoses, and detailed information about hospitalizations and thera-
peutic procedures, inpatient and outpatient physician services, and
prescription drug use. In compliance with the Health Insurance and
Portability and Accountability Act of 1996, all data were de-
identified to protect the privacy of individual patients, physicians,
and hospitals. Because the data were retrospective, preexisting,
and de-identified, RTI International’s institutional review board
determined that this study met all criteria for exemption.
Patients were selected for inclusion if they received at least one
HIV or AIDS diagnosis (International Classification of Diseases, 9th
Revision, Clinical Modification [ICD-9-CM] code 042.xx) between
June 1, 2006, and December 31, 2008. Patients also were required
to have evidence of receipt of a complete ART regimen, defined
as two nucleoside/nucleotide reverse transcriptase inhibitors plus a
third agent (i.e., another nucleoside/nucleotide reverse transcrip-
tase inhibitor, a nonnucleoside/nucleotide reverse transcriptase
inhibitor, a protease inhibitor [PI], a chemokine receipt 5 anta-
gonist, or an integrase inhibitor). ART agents were identified in
the claims database by using National Drug Codes associated with
relevant generic and brand names. Further, patients were required
to remain on the complete regimen for at least 60 days following
first observed uptake and to have evidence of continuous en-
rollment in their health plan during this period.
Patients were grouped into three mutually exclusive cohorts
according to the daily pill count of their complete ART regimen.
Patients were assigned to the single-pill-per-day cohort if they
received an ART regimen consisting of a single pill at any point
during the selection window, regardless of prior or subsequent use
of other regimens. At the time of this study, only coformulated
tenofovir/emtricitabine/efavirenz was available as a single pill per
day. Patients were assigned to the two-pills-per-day cohort if they
received a regimen consisting of two pills per day at any point
during the selection window and if they did not receive a regimen
consisting of a single pill per day at any point during the selection
window. Finally, patients were assigned to the three-or-more-pills-
per-day cohort if they received a regimen consisting of three or
more pills per day at any point during the selection window and if
they did not receive a regimen consisting of either a single pill per
day or two pills per day at any point during the selection window.
Patients were followed from the start of their complete ART
regimen (which defined the study index date) until the earliest date
of regimen discontinuation, disenrollment from the health plan, or
the end of the database (i.e., March 31, 2009). Discontinuation
was defined as 90 consecutive days in which no refills were
observed for any component of the regimen.
Patient characteristics measured at the index date included age,
sex, geographic region, health insurance coverage, and ART
classes received (i.e., nucleoside/nucleotide reverse transcriptase
inhibitors, nonnucleoside/nucleotide reverse transcriptase inhibi-
tors, PIs, ritonavir boosting, and other therapies). The presence of
comorbid medical conditions other than HIV or AIDS was
assessed during the 6-month pre-index period using an established
algorithm, the Charlson Comorbidity Index (CCI) score [12]. This
score is made up of 17 comorbidities (defined by ICD-9-CM
Figure 1. Sample Selection Flow Chart.
doi:10.1371/journal.pone.0031591.g001
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chronic pulmonary disease, which are weighted to correspond
to the severity of the comorbid condition of interest. A higher
comorbidity score represents a higher overall comorbidity burden
during the pre-index period. Additionally, the incidence of other
concomitant mental disorders (ICD-9-CM codes 306.xx to 319.xx)
and drug and alcohol abuse (ICD-9-CM codes 292.xx and 303.xx
to 305.xx) during the 6-month pre-index period also were assessed.
Medication adherence was assessed using the medication
possession ratio (MPR), which has been shown to be the most
widely adopted measure in published claims-based analyses (57%
of all studies) of medication adherence [13] and has been used in
studies of ART adherence among individuals with HIV [14]. For
each patient, the MPR was calculated over the period in which the
patient remained exposed to his or her ART regimen. The MPR,
which is a proxy for refill compliance, generally measures the
proportion of the ART exposure period in which supply was
maintained for all ART components comprising the regimen.
Specifically, MPR was calculated as the number of filled pre-
scription days for all ART regimen components (using the days
supplied in the pharmacy claims) divided by the number of days
from the first observed prescription in the regimen through the
earliest of either the exhaustion of the days supplied of the last
observed prescription or the end of follow-up. For patients in
either of the two- or three-or-more-pill-per-day cohorts, late refills
and resulting days of missing supply for only one ART component
were factored against their adherence measurement. Patients in
the three-or-more pills-per-day cohort with a supply for only two
Table 1. Characteristics of the Study Sample, by Cohort.
Patient Cohort
Single Pill Per Day Two Pills Per Day Three or More Pills Per Day
Total sample (N) 2,365 411 4,297
Female (N, %) 481 20.34% 77 18.73% 990 23.04%
Age (Years) (N, %)
,34 325 13.74% 48 11.68% 393 9.15%
35–44 804 34.00% 145 35.28% 1,394 32.44%
45–54 862 36.45% 148 36.01% 1,782 41.47%
$55 374 36.60% 70 17.03% 728 16.94%
Mean (SD) 44.66 (9.35) 44.96 (9.01) 45.89 (9.02)
Geographic region (N, %)
East 855 36.15% 138 33.58% 1,352 31.46%
South 697 29.47% 120 29.20% 1,541 35.86%
Midwest 566 23.93% 94 22.87% 907 21.11%
West 247 10.44% 59 14.36% 497 11.57%
Health plan type (N, %)
HMO 742 31.37% 111 27.01% 1,221 28.42%
PPO 1,138 48.12% 209 50.85% 2,044 47.57%
Other/missing 485 20.50% 91 22.14% 1,032 24.02%
Payer type (N, %)
Commercial 2,033 85.96% 357 86.86% 3,696 86.01%
Self 220 9.30% 36 8.76% 405 9.43%
Other/missing 112 4.73% 18 4.38% 196 4.56%
Mean (SD) Charlson Comorbidity score
a 0.51 (1.30) 0.63 (1.37) 0.42 (1.15)
Concomitant mental disorders (N, %) 168 7.10% 25 6.10% 219 5.10%
Concomitant drug/alcohol abuse (N, %) 345 14.60% 56 13.60% 619 14.40%
Treatment-naı ¨ve patients (N, %) 988 41.78% 101 24.57% 851 19.80%
ART classes received at index
Nucleoside/nucleotide reverse transcriptase
inhibitors
2,365 100.00% 411 100.00% 4,297 100.00%
Pharmacokinetic enhancers 0 0.00% 0 0.00% 1,240 28.86%
Nonnucleoside reverse transcriptase inhibitors 2,365 100.00% 411 100.00% 1,411 32.84%
Protease inhibitors 0 0.00% 0 0.00% 2,808 65.35%
Entry inhibitors 0 0.00% 0 0.00% 58 1.35%
Integrase inhibitors 0 0.00% 0 0.00% 17 0.40%
Mean (SD) regimen duration (days) 378.58 (253.69) 385.70 (290.49) 433.22 (299.90)
ART=antiretroviral therapy; HMO=health maintenance organization; POS=point of service; PPO=preferred provider organization; SD=standard deviation.
aEvaluated in the 6-month pre-index period.
doi:10.1371/journal.pone.0031591.t001
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considered to have zero adherence for that day. In addition to
reporting the mean (standard deviation) MPR achieved, we also
reported the numbers and percentages of patients achieving
various adherence thresholds (i.e., MPRs of 0.95, 0.90, 0.85, and
0.80, corresponding to 95%, 90%, 85%, and 80% adherence,
respectively).
Hospitalizations were identified from the claims database using
relevant place of service codes. Hospitalizations were observed
from the index date until the earliest date of regimen discontin-
uation, end of enrollment in the health plan, or end of the
database. The number and percentage of patients with at least one
hospitalization were reported, along with the mean (standard
deviation) number of hospitalizations.
All analyses were carried out using SAS (Version 9; Cary, North
Carolina) statistical software. Descriptive analyses were conducted
for all outcome measures and included means and standard
deviations for continuous variables of interest (e.g., MPR) and
frequency distributions of categorical variables of interest (e.g.,
geographic region). All descriptive analyses were stratified by each
pill-count cohort.
Multivariate logistic regression analyses were conducted to
assess the relationship between the number of pills per day,
adherence, and hospitalization. The dependent variables included
binary indicators for achieving an MPR threshold of 0.95 (i.e.,
95% adherence) and whether the patient was hospitalized during
exposure to the ART regimen. Independent variables included in
each logistic model were as follows: treatment regimen received
(i.e., single pill per day and two pills per day vs. the reference
category of three or more pills per day), age, sex, geographic
region, health plan type, payer type, CCI score, treatment-naı ¨ve
status, pre-index presence of mental health disorders, and pre-
index presence of alcohol or drug abuse disorders. Since the
number of pills received per day and achieving a 95% adherence
threshold were likely proxies for each other, two separate models
assessing hospitalization risk were estimated. Odds ratios (ORs)
were reported for all covariates.
Results
A total of 7,073 patients met the selection criteria (Figure 1).
Most patients received their ART regimen as three or more pills
per day (60.8% of patients) or as a single pill per day (33.4% of
patients). On average, patients were approximately 45 years of
age. Approximately one-fifth of patients were female (Table 1).
Across all three cohorts, most patients were covered by com-
mercial health insurance, and the average CCI score was appro-
ximately the same. Furthermore, the incidence of concomitant
mental disorders and drug and alcohol abuse diagnoses did not
vary substantially by cohort. Patients tended to remain on the
observed ART regimen for approximately 13 months, and patients
receiving three or more pills per day had a mean regimen duration
Table 2. Adherence to ART Regimens, by Cohort.
Patient Cohort P Values
a






Single Pill Per Day
vs. Three or More
Pills Per Day
Two Pills Per Day
vs. Three or More
Pills Per Day
MPR
Mean (SD) 0.92 (0.09) 0.90 (0.10) 0.90 (0.09) 0.006 ,0.0001 0.188
Median 0.95 0.94 0.92 0.0020 ,0.0001 0.004
Minimum, maximum 0.50 1.00 0.17 1.00 0.20 1.00
0.95 threshold (N, %)
MPR$0.95 1,114 47.10% 168 40.88% 1,468 34.16% 0.0194 ,0.0001 0.006
MPR,0.95 1,251 52.90% 243 59.12% 2,829 65.84%
0.90 threshold (N, %)
MPR$0.90 1,698 71.80% 281 68.37% 2,664 62.00% 0.1563 ,0.0001 0.011
MPR,0.90 667 28.20% 130 31.63% 1,633 38.00%
0.85 threshold (N, %)
MPR$0.85 1,963 83.00% 319 77.62% 3,316 77.17% 0.0084 ,0.0001 0.837
MPR,0.85 402 17.00% 92 22.38% 981 22.83%
0.80 threshold (N, %)
MPR$0.80 2,128 89.98% 355 86.37% 3,703 86.18% 0.0282 ,0.0001 0.911
MPR,0.80 237 10.02% 56 13.63% 594 13.82%
MPR quintiles (N, %)
0.8–1 2,128 89.98% 355 86.37% 3,703 86.18% 0.0282 ,0.0001 0.911
0.6–0.79 210 8.88% 51 12.41% 536 12.47% 0.0236 ,0.0001 0.970
0.4–0.59 27 1.14% 3 0.73% 56 1.30% 0.4562 0.5694 0.318
0.2–0.39 0 0.00% 1 0.24% 1 0.02% — — —
,0.2 0 0.00% 1 0.24% 1 0.02% — — —
ART=antiretroviral therapy; MPR=medication possession ratio; SD=standard deviation.
aP values calculated from Students t-test for mean MPR, Wilcoxon rank sum tests for median MPR, and chi-square for distribution by MPR threshold.
doi:10.1371/journal.pone.0031591.t002
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patients receiving fewer than three pills per day (i.e., mean
regimen duration of 433 days among patients receiving three or
more pills per day vs. 379 and 386 days among patients receiving a
single pill per day and two pills per day, respectively). Forty-two
percent of patients receiving a single pill per day were treatment
naı ¨ve, compared with 25% of patients receiving two pills per day
and 20% of patients receiving three or more pills per day.
Patients receiving a single pill per day had significantly better
adherence when compared with patients receiving multiple pills
per day. Approximately 47% of patients receiving a single pill per
day achieved 95% adherence or greater, compared with 41% of
patients receiving two pills per day and 34% of patients receiving
three or more pills per day (P=0.019 for single pill vs. two pills;
P,0.001 for single pill vs. three or more pills). Mean (standard
deviation) MPR was 0.92 (0.09) among patients receiving a single
pill per day, 0.90 (0.10) among patients receiving two pills per day,
and 0.90 (0.09) among patients receiving three or more pills per
day (P,0.01 for single pill vs. two pills and for single pill vs. three
or more pills) (Table 2).
Multivariate logistic regression models showed that receiving a
single pill per day was associated with a 59% greater likelihood of
achieving a 95% adherence threshold, compared with receiving
three or more pills per day (OR=1.587, P,0.001). The following
were also associated with a greater likelihood of achieving a
95% adherence threshold (Table 3): receiving two pills per day
versus three or more pills per day (OR=1.346, P=0.006), being
treatment naı ¨ve versus treatment experienced (OR=1.378, P,
0.001), and receiving treatment in 2008 versus 2006 (OR=1.418,
P#0.001). The presence of a concomitant drug or alcohol abuse
diagnosis during the 6-month pre-index period was found to be
associated with a significantly lower likelihood of achieving a 95%
adherence threshold (OR=0.599, P,0.001), as was being female
(OR=0.869, P=0.027).
Table 3. Predictors of Achieving a 95% Adherence Threshold to ART, Using Multivariate Logistic Regression.
Odds Ratio Lower 95% CI Upper 95% CI P Value
Treatment regimen (vs. three or more pills per day)
Single pill per day 1.587 1.415 1.780 ,0.001
Two pills per day 1.346 1.091 1.660 0.006
Female (vs. male) 0.869 0.767 0.984 0.027
Age (years) (vs. ,35)
35–44 1.074 0.901 1.279 0.426
45–54 1.136 0.955 1.351 0.151
55–64 1.250 1.025 1.523 0.027
$65 1.671 0.470 5.944 0.428
Geographic region (vs. East)
South 0.956 0.830 1.101 0.530
Midwest 0.909 0.786 1.050 0.194
West 0.619 0.509 0.752 ,0.001
Health plan type (vs. HMO)
PPO 1.095 0.962 1.246 0.169
POS 0.879 0.735 1.051 0.156
Indemnity 1.057 0.829 1.348 0.653
Consumer directed 1.257 0.989 1.597 0.061
Other/missing 1.062 0.613 1.841 0.829
Payer type (vs. commercial)
Medicaid 0.529 0.375 0.745 ,0.001
Medicare 0.885 0.575 1.361 0.577
Self 0.691 0.564 0.848 ,0.001
Other/missing 2.046 0.609 6.873 0.247
Charlson Comorbidity score (vs. #1)
Between 1 and 2 1.022 0.785 1.330 0.873
Between 2 and 3 0.949 0.728 1.238 0.701
.3 0.863 0.647 1.152 0.319
Treatment naı ¨ve pre-index (vs. treatment experienced) 1.378 1.209 1.57 ,0.001
Had a mental disorder diagnosis 1.033 0.895 1.192 0.655
Had a drug or alcohol abuse diagnosis 0.599 0.476 0.753 ,0.001
Received treatment in 2007 (vs. 2006) 0.926 0.798 1.076 0.316
Received treatment in 2008 (vs. 2006) 1.418 1.194 1.685 ,0.001
ART=antiretroviral therapy; CI=confidence interval; HMO=health maintenance organization; POS=point of service; PPO=preferred provider organization.
doi:10.1371/journal.pone.0031591.t003
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significantly (P,0.001) lower rate of hospitalization, regardless of
pill burden, compared with patients who did not achieve a 95%
adherence threshold (Figure 2). Specifically, among patients who
received a single pill per day, 6.6% of patients who achieved a 95%
adherencethresholdhadatleastonehospitalization,compared with
11.4% of patients who did not achieve a 95% adherence threshold.
Similarly, among patients who received two pills per day, 6.6% of
patients who achieved a 95% adherence threshold had at least one
hospitalization, compared with 15.2% of patients who did not
achieve a 95% adherence threshold. Among patients who received
three or more pills per day, 7.8% of patients who achieved a 95%
adherencethresholdhadatleastonehospitalization,compared with
12.1% of patients who did not achieve a 95% adherence threshold.
Our multivariate logistic regression models showed that achiev-
ing a 95% adherence threshold was associated with a significantly
lower risk of hospitalization when compared with not achieving a
95% adherence threshold (OR=0.572, P,0.001) (Table 4). When
we controlled for adherence, we observed that patients were
significantly more likely to be hospitalized if they had a concomitant
mental disorder diagnosis versus no concomitant mental disorder
diagnosis (OR=1.388, P=0.002), had a concomitant drug or
alcohol abuse diagnosis versus no concomitant drug or alcohol
abuse diagnosis (OR=1.884, P,0.001), were female versus male
(OR=1.249, P=0.022), were covered by Medicare versus
commercial insurance (OR=2.156, P=0.005), were self-insured
versus covered by commercial insurance (OR=1.412, P=0.025),
or had a CCI score greater than 1 (OR increased with increasing
CCI score, from 2.265 among patients with a CCI between 1 and 2
to 5.094 among patients with a CCI greater than 3, all P,0.001).
Similarly, in separate logistic models, patients who received a
single pill per day had a significantly lower likelihood of being
hospitalized, compared with patients receiving three or more pills
per day (OR=0.764, P=0.003) (Table 5). When controlling for
treatment regimen received, we observed that patients were
significantly more likely to be hospitalized if they had a
concomitant drug or alcohol abuse diagnosis versus having
no concomitant drug or alcohol abuse diagnosis (OR=2.023,
P,0.001), had a concomitant mental disorder diagnosis versus
having no concomitant mental disorder diagnosis (OR=1.372,
P=0.003), were female versus male (OR=1.260, P=0.017), were
covered by Medicare versus commercial insurance (OR=2.173,
P=0.004), were self-insured versus covered by commercial
insurance (OR=1.463, P=0.013), or had a CCI score greater
than 1 (OR increased with increasing CCI score, from 2.279
among patients with a CCI score between 1 and 2 to 5.147 among
patients with a CCI score greater than 3, all P,0.001).
In the estimated logistic regression analysis that controlled for
the number of pills received per day and clinical and demographic
characteristics, the adjusted rate of hospitalization was found to be
significantly lower for patients receiving a single pill per day
compared with patients receiving three or more pills per day (i.e.,
7.7% of patients receiving a single pill per day were predicted to
be hospitalized vs. 9.9% of patients receiving three or more pills
per day) (Figure 3). Further, there was a 24% lower risk of hospi-
talization among patients receiving a single pill per day compared
with patients receiving three or more pills per day.
Discussion
This retrospective database analysis examined adherence to
ART regimens among patients with HIV or AIDS. The rate of
hospitalization and the predictors of hospitalization also were
assessed. This study found that patients receiving a single pill per
day had significantly better adherence and consistently achieved
higher adherence thresholds than patients receiving multiple pills
per day. Additionally, patients who achieved a 95% adherence
threshold had a significantly lower rate of hospitalization (P,
0.001) compared with patients who were nonadherent to therapy,
regardless of their pill burden. Also, patients who received a single
pill per day were significantly less likely to be hospitalized than
patients who received three or more pills per day.
Figure 2. Frequency of Hospitalizations, by Cohort
a.
doi:10.1371/journal.pone.0031591.g002
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and Human Services and the International AIDS Society-USA
currently list four regimens as preferred for initial therapy. All four
contain coformulated tenofovir-emtricitabine, with the remainder
of the regimen consisting of 1) efavirenz or 2) ritonavir-boosted
atazanavir or 3) ritonavir-boosted darunavir or 4) raltegravir [7].
The first three of these regimens are administered once daily, while
the raltegravir-based treatment requires twice-daily dosing. Teno-
fovir-emtricitabine-efavirenz is the only preferred regimen currently
available as a single pill per day; this was the most commonly
chosen regimen in our study sample, used in 33% of patients. The
atazanavir- and raltegravir-based treatments contain three pills, and
darunavir-based treatments contain four. Coformulated abacavir-
lamivudine plus efavirenz was the only available two-pill regimen at
the time of our study; this is listed as an alternative initial treatment
in the above-mentioned guidelines.
Consistent with previous literature, we found that patients in our
study generally were adherent to ART, regardless of the number
of pills received per day [9,10]. Patients who received treatment as
a single pill per day had significantly better adherence than
patients who received multiple pills per day. Furthermore, this
difference (approximately 2.2%) was in line with the increased
adherence effect reported by Parienti and colleagues in a meta-
analysis of 11 studies examining the difference in adherence
between once-daily dosed and twice-daily dosed regimens [15].
Specifically, Parienti and colleagues reported a 2.9% increase in
adherence with a once-daily dosed regimen compared with a
twice-daily dosed regimen [15].
Among patients receiving complex, multi-pill regimens, adher-
ence estimates typically have ranged from 60% to 70% [5,16,17].
Achieving optimal outcomes in HIV/AIDS treatment, however,
requires a much higher, sustained level of adherence throughout a
patient’s lifetime [18]. Studies conducted on patients receiving
older ART regimens have suggested that an ART adherence rate
of at least 95% was required to achieve a lower risk of virologic
failure, fewer hospital days, and reduced morbidity and mortality
in patients with HIV or AIDS [5,16,19]. Simpler regimens with
longer half-lives may allow for a lesser degree of adherence [20],
but the goal of maximum adherence remains an important one in
clinical care. Therefore, reducing pill burden to a single pill per
day may improve adherence to ART and reduce the risk of
hospitalization for patients with HIV or AIDS [15]. On the basis
Table 4. Predictors of Hospitalization, Using Multivariate Logistic Regression and Controlling for Adherence Threshold.
Odds Ratio Lower 95% CI Upper 95% CI P Value
Achieved a 95% adherence threshold 0.572 0.479 0.682 ,0.001
Female (vs. male) 1.249 1.032 1.510 0.022
Age (years) (vs. ,35)
35–44 0.815 0.619 1.072 0.143
45–54 0.829 0.632 1.087 0.175
55–64 1.013 0.746 1.375 0.934
$65 0.558 0.065 4.746 0.593
Geographic region (vs. East)
South 1.101 0.873 1.390 0.416
Midwest 1.130 0.893 1.429 0.308
West 0.964 0.704 1.320 0.817
Health plan type (vs. HMO)
PPO 1.199 0.964 1.491 0.103
POS 1.271 0.956 1.692 0.099
Indemnity 1.285 0.871 1.897 0.206
Consumer directed 0.612 0.364 1.029 0.064
Other/missing 0.871 0.374 2.026 0.748
Payer type (vs. commercial)
Medicaid 1.080 0.674 1.730 0.748
Medicare 2.156 1.260 3.692 0.005
Self 1.412 1.044 1.910 0.025
Other/missing 2.336 0.460 11.862 0.306
Charlson Comorbidity score (vs. #1)
Between 1 and 2 2.265 1.609 3.188 ,0.001
Between 2 and 3 2.446 1.762 3.396 ,0.001
Greater than 3 5.094 3.759 6.904 ,0.001
Treatment naı ¨ve pre-index (vs. treatment experienced) 1.160 0.972 1.385 0.100
Had a mental disorder diagnosis 1.388 1.130 1.705 0.002
Had a drug or alcohol abuse diagnosis 1.884 1.433 2.477 ,0.001
CI=confidence interval; HMO=health maintenance organization; POS=point of service; PPO=preferred provider organization.
doi:10.1371/journal.pone.0031591.t004
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coformulated combinations are under investigation [21,22].
Our adherence estimates for patients receiving a single pill
per day were slightly lower than previously reported estimates
(i.e., 0.92 reported in the present analysis vs. 0.96 reported by both
Hodder et al. and Airoldi et al.) [9,10]. The differences in
adherence estimates may be due to the fact that both the Hodder
and Airoldi studies examined patients in a clinical trial setting,
while our patients were identified using health care claims (i.e.,
a real-world treatment setting). Additionally, as expected, our
estimate for patients receiving a single pill per day were higher
than the estimate (0.86) previously reported by Bangsberg and
colleagues in a homeless and marginally housed population [23].
Similar to previous studies [24,25], we found that patients who
were adherent to therapy were less likely to have a hospital stay.
Additionally, this study also attempted to control for various
baseline differences in the study populations and the effects these
differences may have had on rates of adherence and hospitaliza-
tion. Specifically, multivariate logistic regressions were undertaken
that controlled for patient demographics, treatment characteristics
(i.e., treatment naı ¨ve vs. experienced, type of ART received, year
ART received), and clinical characteristics (i.e., CCI score,
concomitant mental disorder, drug and alcohol abuse diagnoses).
We found a number of factors were associated with an increased
risk of poor adherence, including having Medicaid, Medicare, or
no insurance; having a CCI score greater than 3; having a drug
or alcohol abuse diagnosis; and being treatment experienced.
Similarly, having Medicare or no insurance, a CCI score greater
than 1, or a concomitant mental disorder or drug or alcohol abuse
diagnosis was associated with an increased risk of hospitalization.
In the logistic regression model assessing predictors of achieving
a 95% adherence level as a function of the number of pills received
per day, the comparator cohort was patients receiving three or
more pills per day. Separate analyses were conducted using the
single-pill-per-day cohort as the comparator. When the single-pill-
per-day variable was used as the comparator, no significant
differences based on the multivariate model were observed
between patients receiving a single pill per day and patients
Table 5. Predictors of Hospitalization, Using Multivariate Logistic Regression and Controlling for Treatment Regimen Received.
Odds Ratio Lower 95% CI Upper 95% CI P Value
Treatment regimen (vs. three or more pills per day)
Single pill per day 0.764 0.638 0.915 0.003
Two pills per day 1.001 0.721 1.388 0.997
Female (vs. male) 1.260 1.042 1.524 0.017
Age (years) (vs. ,35)
35–44 0.801 0.609 1.054 0.113
45–54 0.799 0.609 1.049 0.106
55–64 0.972 0.717 1.319 0.856
$65 0.527 0.062 4.467 0.557
Geographic region (vs. East)
South 1.100 0.871 1.387 0.424
Midwest 1.142 0.903 1.443 0.267
West 1.006 0.735 1.376 0.972
Health plan type (vs. HMO)
PPO 1.176 0.947 1.462 0.143
POS 1.274 0.958 1.694 0.096
Indemnity 1.233 0.835 1.819 0.292
Consumer directed 0.590 0.351 0.992 0.046
Other/missing 0.871 0.378 2.007 0.745
Payer type (vs. commercial)
Medicaid 1.134 0.709 1.813 0.599
Medicare 2.173 1.275 3.706 0.004
Self 1.463 1.084 1.976 0.013
Other/missing 2.106 0.418 10.618 0.367
Charlson Comorbidity score (vs. #1)
Between 1 and 2 2.279 1.621 3.205 ,0.001
Between 2 and 3 2.490 1.796 3.452 ,0.001
Greater than 3 5.147 3.805 6.963 ,0.001
Treatment naı ¨ve pre-index (vs. treatment experienced) 1.153 0.963 1.380 0.121
Had a mental disorder diagnosis 1.372 1.118 1.684 0.003
Had a drug or alcohol abuse diagnosis 2.023 1.541 2.654 ,0.001
CI=confidence interval; HMO=health maintenance organization; POS=point of service; PPO=preferred provider organization.
doi:10.1371/journal.pone.0031591.t005
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observed for the unadjusted mean and median adherence values,
along with the percentage of patients achieving a 95% adherence
level, among patients receiving a single pill per day versus patients
receiving two pills per day. We hypothesize that the lack of
significance based on the multivariate models was likely due to the
small number of patients who received two pills per day.
Our study has several limitations common to observational
claims database analyses. Adherence was measured from filled
prescriptions (as opposed to the number of tablets ingested);
however, studies have suggested that pharmacy refill rates are a
good proxy for actual medication adherence [26].
Because patients were not randomized to the different
treatments, we cannot exclude unmeasured confounding factors
that may have influenced our outcomes. Among the most
important of these factors in this study is that multiple trials have
shown resistance or virologic failure is significantly less common in
boosted PI treatments than in nonnucleoside/nucleotide reverse
transcriptase inhibitor-based treatments [27,28]. As such, clini-
cians may have preferentially prescribed the boosted-PI–contain-
ing regimens (all of which contain three or more pills per day) to
their less-adherent patients. Although we attempted to control for
some of these variables through use of multivariable models that
include some of these factors (substance abuse and psychiatric
diagnoses), residual confounding may remain.
A large proportion of HIV-treated individuals (20.5% of the
total HIV-treated population) were excluded from the analysis due
to receiving incomplete ART regimens; we did not have sufficient
data on these patients to explain why their regimens were
incomplete. However, a previous study found that physician
medication errors are somewhat common in individuals with HIV,
with the most common error occurring for boosted PIs (estimated
at 5.3% of patients), which may explain some of the incomplete
regimens observed in our analysis [29]. Increased adoption of
fixed-dose combinations as part of HIV treatment may help to
alleviate the issue of incomplete regimens.
This study examined only three years of data, and therefore
may not account for secular trends in adherence counseling and
the decision for starting treatment. Since this study used
retrospective claims data, it was not possible to determine the
daily dosing frequency over which those pills were distributed (e.g.,
twice daily, three times daily). During the study period, the only
available single-pill ART regimen was coformulated efavirenz/
emtricitabine/tenofovir disoproxil fumarate, and abacavir/lami-
vudine plus efavirenz was the only two-pill-per-day treatment. It is
possible that these results would not be generalizable to other one-
and two-pill-per-day treatments if they had different efficacy and
toxicity profiles. Finally, because managed care data were used,
results from this study may not be applicable to Medicaid or
uninsured populations.
In summary, this study found that patients who receive ART as
a single pill per day are significantly more likely to be highly
adherent to therapy. Furthermore, receiving a single pill per day
was associated with a lower risk of hospitalization when compared
with receiving multiple pills per day. Although this study could not
assess causality, it did show that receiving ART as a single pill per
day was associated with potential clinical and economic benefits.
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